Aadi Bioscience, Inc. (NASDAQ:AADI) Sees Large Increase in Short Interest

Aadi Bioscience, Inc. (NASDAQ:AADI - Get Free Report) was the target of a significant increase in short interest in January. As of January 31st, there was short interest totalling 706,400 shares, an increase of 49.4% from the January 15th total of 472,700 shares. Based on an average trading volume of 357,800 shares, the days-to-cover ratio is currently 2.0 days. Currently, 3.5% of the company's stock are short sold.

Aadi Bioscience Trading Down 0.8 %

NASDAQ AADI traded down $0.02 on Friday, hitting $2.59. 108,349 shares of the company were exchanged, compared to its average volume of 182,094. The company has a market cap of $63.97 million, a PE ratio of -1.14 and a beta of 0.64. Aadi Bioscience has a 12 month low of $1.21 and a 12 month high of $3.81. The stock has a fifty day moving average of $2.92 and a 200-day moving average of $2.27.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Northern Trust Corp raised its holdings in Aadi Bioscience by 33.1% during the fourth quarter. Northern Trust Corp now owns 91,151 shares of the company's stock worth $288,000 after buying an additional 22,677 shares during the last quarter. QVT Financial LP acquired a new position in Aadi Bioscience during the fourth quarter worth $7,300,000. Geode Capital Management LLC raised its holdings in Aadi Bioscience by 4.1% during the fourth quarter. Geode Capital Management LLC now owns 217,294 shares of the company's stock worth $686,000 after buying an additional 8,546 shares during the last quarter. BML Capital Management LLC raised its holdings in Aadi Bioscience by 5.0% during the fourth quarter. BML Capital Management LLC now owns 2,100,000 shares of the company's stock worth $6,626,000 after buying an additional 100,000 shares during the last quarter. Finally, Peapod Lane Capital LLC acquired a new position in Aadi Bioscience during the fourth quarter worth $1,397,000. 52.08% of the stock is owned by institutional investors.

About Aadi Bioscience

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.